Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV‐1 Infection-Reference-Cited by-同舟云学术

Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV‐1 Infection

Published:2020-11-16 Issue:1 Volume:16 Page:2000023
ISSN:1860-6768
Container-title:Biotechnology Journal
language:en
Short-container-title:Biotechnol. J.

Author:

Romito Marianna¹²,Juillerat Alexandre³,Kok Yik Lim⁴⁵,Hildenbeutel Markus¹²,Rhiel Manuel¹²,Andrieux Geoffroy²⁶⁷,Geiger Johannes⁸,Rudolph Carsten⁸,Mussolino Claudio¹²,Duclert Aymeric⁹,Metzner Karin J.⁴⁵,Duchateau Philippe⁹,Cathomen Toni¹²^ORCID,Cornu Tatjana I.¹²^ORCID

Affiliation:

1. Institute for Transfusion Medicine and Gene Therapy Center for Chronic Immunodeficiency Medical Center—University of Freiburg Freiburg 79106 Germany

2. Faculty of Medicine University of Freiburg Freiburg 79110 Germany

3. Cellectis, Inc. New York NY 10016 USA

4. Division of Infectious Diseases and Hospital Epidemiology University Hospital Zurich Zurich 8091 Switzerland

5. Institute of Medical Virology University of Zurich Zurich 8057 Switzerland

6. Institute of Medical Bioinformatics and Systems Medicine Medical Center – University of Freiburg Freiburg 79110 Germany

7. German Cancer Consortium (DKTK), Freiburg Germany and German Cancer Research Center (DKFZ) Heidelberg 69120 Germany

8. ethris GmbH Planegg 81249 Germany

9. Cellectis S.A. Paris 75013 France

Publisher

Wiley

Subject

Molecular Medicine,Applied Microbiology and Biotechnology,General Medicine